Stay updated on OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial
Sign up to get notified when there's something new on the OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial page.

Latest updates to the OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision v3.3.4 was added and v3.3.3 removed in the history. This is a minor platform version update and does not alter trial data or content.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedAdded Revision: v3.3.3 to the page footer and removed the HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check53 days agoChange DetectedThe Record History now shows a new revision entry: v3.3.2 has been added, replacing the previous v3.3.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedThe record history shows an addition of Revision: v3.3.1 and a deletion of Revision: v3.2.0. These updates are administrative and do not affect study data or displayed information; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check68 days agoChange DetectedThe government funding status notice at the top of the page was removed. It previously informed users about potential delays and operating status.SummaryDifference0.7%

- Check82 days agoChange DetectedThe history shows multiple versions with updates to recruitment status, study status, and study design. The version list now extends up to 2021-06-07.SummaryDifference0.1%

Stay in the know with updates to OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the OptiPOM: Alternate Day Pomalidomide in Refractory MM Clinical Trial page.